← All trials
NCT04854512
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2021
- Primary completion
- Dec 1, 2023
- Completion date
- Jun 30, 2024
- First posted
- Apr 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 675
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Anjie Biomedical Technology Co., Ltd.Lead sponsor
- Anji PharmaStudy chair
- Anji PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.